BOT basically looking at Sofdra being the leading treatment for H/h in the U.S and obtain @ 50% of the market of H/h existing patients initially. Around 1.8 mill patients.(x monthly treatments x. x.????)= $$$$
Sofdra has meet the primary endpoints with unmatched safety & efficacy, with 9/10 patient having a "clinically meaningful experience".
Also superfast turnaround of product to patient, (2-4days)
1% of market to give us @ $300 mill revenue.. 50% would be.............................$
Ann: Botanix Commercial Day Webinar Presentation, page-53
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.5¢ | 37.5¢ | $960.2K | 2.538M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 698106 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 292741 | 17 |
View Market Depth
| Last trade - 13.33pm 29/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |